What biomarker tests are recommended for CLL

Biomarker Testing for CLL: What You Should Know

Biomarkers are specific characteristics found in cancer cells or blood that help doctors understand your disease and guide treatment decisions. For CLL (chronic lymphocytic leukemia), several important biomarker tests are recommended to assess your condition and predict how your disease may behave.

Key Biomarkers Tested in CLL

Genetic and Chromosomal Markers

According to NCCN Guidelines for CLL, doctors typically evaluate several genetic abnormalities that have important implications for your prognosis and treatment:

FISH (Fluorescence In Situ Hybridization) Testing:

• del(17p) - deletion of chromosome 17p: This is associated with more aggressive disease and traditionally required different treatment approaches
• del(11q) - deletion of chromosome 11q: Associated with intermediate risk
• Trisomy 12 - extra copy of chromosome 12: Associated with intermediate risk
• Normal cytogenetics - no major deletions: Generally more favorable

Gene Mutations

The NCCN Guidelines identify several important mutations that affect prognosis and treatment selection:

• TP53 mutations - Associated with more aggressive disease and poorer outcomes
• NOTCH1 mutations - Linked to higher risk of transformation to Richter syndrome (when CLL transforms into a more aggressive lymphoma)
• SF3B1 mutations - Associated with disease progression
• ATM mutations - Affects disease behavior and treatment response
• BIRC3 mutations - Associated with more aggressive disease

IGHV Mutation Status

This test examines whether your CLL cells have mutated immunoglobulin heavy chain (IGHV) genes:

• IGHV-mutated - Generally associated with better prognosis and slower disease progression
• IGHV-unmutated - Associated with more aggressive disease and higher risk of Richter transformation

Laboratory Tests

Beyond genetic testing, standard blood work includes:

• Complete blood count (CBC) - Measures white blood cells, red blood cells, and platelets
• LDH (lactate dehydrogenase) - Elevated levels may indicate more aggressive disease
• Beta-2 microglobulin - Higher levels suggest more aggressive disease
• Flow cytometry - Confirms CLL diagnosis and characterizes the leukemia cells

Why These Tests Matter

According to NCCN Guidelines, these biomarkers help your oncologist:

• Predict disease behavior - Some markers indicate faster or slower progression
• Guide treatment selection - Certain mutations may make you a candidate for specific targeted therapies (like BTK inhibitors or venetoclax)
• Assess transformation risk - Particularly NOTCH1 and TP53 mutations increase risk of Richter transformation, which requires different management
• Determine prognosis - Help estimate how your disease may progress over time

Questions to Ask Your Healthcare Team

1. Which biomarker tests have been done on my CLL cells, and what were the results?
2. What do my specific genetic findings mean for my prognosis and treatment options?
3. Do I have any high-risk mutations that would change my treatment approach?
4. How often should these biomarkers be retested, and what would trigger retesting?
5. Are there any clinical trials available that target my specific biomarkers?

Important Context

Not all patients need every test immediately. Your oncologist will determine which biomarkers are most relevant based on your individual situation, whether you're newly diagnosed or have relapsed disease, and what treatment decisions need to be made.

The NCCN Guidelines emphasize that biomarker testing should guide personalized treatment planning, but your complete clinical picture—including your symptoms, disease stage, age, and overall health—also factors into your care plan.

---

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.